Total votes: 3

Cash reserves (at market value): Dec 2011 were approx. $18.5 million

estimated cash burn per year by CEO is $9M p.a.

Shares held by:

  Institutions/Funds: ~ 32%

  Retail investors: ~ 40%

  Professional investors: ~ 28%

Possible events coming:

In February 2011, Circadian launched its first diagnostic product, a serum based test to detect VEGF-D as a marker for respiratory disease. The company is expecting to enter clinical trials with VGX-100 by 2011Q4. Circadian targets to have clinical proof of principal from Phase 2 studies with VGX-100 by mid 2014. Circadian is looking to enter into a partnership with VGX-100 in the next 1-2 years.

 - click here for more possible events...

Overview:
Circadian has moved from being a biotechnology investor and incubator to a developer of angiogenesis-based therapeutics for cancer and other serious diseases. More specifically developing antibody therapies with an anti-angiogenic approach.

The portfolio covering key targets (Vascular Endothelial Growth Factors C and D) for the treatment of diseases associated with angiogenesis has been accumulated in Circadian’s unlisted subsidiary, Vegenics Limited. On August 14, 2008, Circadian announced that it had completed its acquisition of the Ludwig Institute for Cancer Research Ltd’s (LICR) and Licentia Limited’s (Licentia) combined 33% interest in Vegenics. This increased Circadian’s interest in Vegenics Limited from 67% to 100%.

Has licensing deals with the following comapnies:
 - ImClone Systems Inc (recently acquired by Eli Lilly & Co.
 - Healthscope Limited (ASX:HSP) developing cancer diagnostic test

People:
Of note the "Product Development Advisory Committee" has strong experience in international drug developmentand oncology.
 – Errol Malta (Chair): ex Amgen
 – George Morstyn: ex CMO Amgen
 – Russell Howard: CEO Nasdaq listed Maxygen
 – Ralph Smalling: ex Amgen Reg Affairs
 – Richard Morgan: ex Glaxo-Wellcome
 – Carlo Montagner: ex Aventis, Schering, Abraxis

Top 10 Sahreholders include institutional and professional investors:
 - Packer and Co Limited 17.1
 - Select Asset Management Ltd 8.1
 - Ludwig Institute for Cancer Research 5.7
 - Licentia Ltd 5.6
 - Leon Serry 4.6
 - HSBC Custody Nominees 2.7
 - Chemical Trustee Limited 2.3
 - Jagen Pty Ltd 2.2
 - JFF Steven Pty Ltd 1.8
 - Audivac Pty Ltd 1.7

Total 10 shareholders own 51.8%

Related comapnies or competition:
 - Bionomics, see 
         http://www.bioinvest.com.au/company/Bionomics